Brief: MeiraGTx Holdings Says Primary Study Objective Of Safety And Tolerability Was Met

MeiraGTx Holdings

15/10/2024 12:15

Oct 15 (Reuters) - MeiraGTx Holdings PLC  MGTX.O :
    * MEIRAGTX HOLDINGS: POSITIVE DATA FROM RANDOMIZED,
SHAM-CONTROLLED CLINICAL BRIDGING STUDY OF AAV-GAD FOR TREATMENT
OF PARKINSON'S DISEASE
    * MEIRAGTX HOLDINGS PLC: PRIMARY STUDY OBJECTIVE OF SAFETY
AND
TOLERABILITY WAS MET
    * MEIRAGTX HOLDINGS: SIGNIFICANT & CLINICALLY MEANINGFUL
IMPROVEMENTS FROM BASELINE DEMONSTRATED FOR KEY EFFICACY
ENDPOINTS AT 26 WEEKS
    * MEIRAGTX HOLDINGS: AAV-GAD WAS SAFE & WELL TOLERATED, WITH
NO
SERIOUS ADVERSE EVENTS RELATED TO AAV-GAD TREATMENT

Source text for Eikon:  ID:nGNX23ZH5k 
Further company coverage:  MGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))